Linked public records Regulatory actions involving BPC-157 FDA advisory committee to review seven peptide-related bulk drug substances Scheduled Scheduled public meeting FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List
Today, it is used in both medical and cosmetic applications due to its ability to repair damaged tissue, reduce inflammation, and stimulate collagen and elastin production
For opened multi-dose vials without a different manufacturer date, CDC summarizes USP guidance as 28 days after first puncture. What refrigeration is required for reconstituted peptides
The FDA announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding potential inclusion of GHK-Cu on the 503A bulks list